Белок DDAH1: биологические функции, роль в процессах канцерогенеза

Закрыть метаданные

Рекомендуем статьи по данной теме:

Приверженность врачей следованию клиническим рекомендациям: влияние на смертность при лечении солидных опухолей (систематический обзор и метаанализ). Медицинские технологии. Оценка и выбор. 2024;(2):28-39

Диметиларгинин диметиламиногидролаза 1 (Dimethylarginine Dimethylaminohydrolase 1 — DDAH1) — важнейший фермент, способный разрушать асимметричный диметиларгинин, эндогенный ингибитор синтазы оксида азота. Считается, что DDAH1 регулирует выработку эндотелиального NO через молекулярный путь DDAH-ADMA-NOS. Повышенная экспрессия DDAH1 и последующее увеличение выработки NO связаны с канцерогенезом. В частности, DDAH1 участвует в создании опухолевыми клетками сосудистой сети — васкулогенной мимикрии, которая тесно связана с прогрессированием опухоли и плохим прогнозом для пациента. Именно поэтому DDAH1 может являться потенциальной терапевтической мишенью для лечения онкологических заболеваний.

Ключевые слова:

DDAH1

ADMA

солидные опухоли

васкулогенная мимикрия

Авторы:

Просекина Е.А.

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России;
Национальный исследовательский Томский государственный университет

ORCID: 0000-0002-1235-3829

Шапкина В.А.

Санкт-Петербургский государственный университет

ORCID: 0000-0003-1843-2808

Карпов А.Е.

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России

ORCID: 0000-0003-3913-9619

Федоруцева Е.Ю.

Национальный исследовательский Томский государственный университет

ORCID: 0009-0001-3577-8379

Артемьева А.С.

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России

ORCID: 0000-0002-2948-397X

Дата поступления:

08.06.2024

Дата принятия в печать:

30.10.2024

Список литературы:

Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun. 1987;148(2):671-677. https://doi.org/10.1016/0006-291X(87)90929-6
Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343Pt. 1(Pt. 1):209-214. https://doi.org/10.1042/0264-6021:3430209
Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4(4):33-40. https://doi.org/10.1016/S1567-5688(03)00032-1
Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics. 2000;68(1):101-105. https://doi.org/10.1006/GENO.2000.6262
Mishima T, Hamada T, Ui-Tei K, Takahashi F, Miyata Y, Imaki J, Suzuki H, Yamashita K. Expression of DDAH1 in chick and rat embryos. Brain Res Dev Brain Res. 2004;148(2):223-232. https://doi.org/10.1016/j.devbrainres.2003.09.021
Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007;101(6):627-635. https://doi.org/10.1161/CIRCRESAHA.107.158915
Altmann KS, Havemeyer A, Beitz E, Clement B. Dimethylarginine-dimethylaminohydrolase-2 (DDAH-2) does not metabolize methylarginines. Chembiochem. 2012;13(17):2599-2604. https://doi.org/10.1002/CBIC.201200499
Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13(2):198-203. https://doi.org/10.1038/NM1543
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092-3095. https://doi.org/10.1161/01.CIR.99.24.3092
Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003;92(2):226-233. https://doi.org/10.1161/01.RES.0000052990.68216.EF
Achan V, Tran CTL, Arrigoni F, Whitley GSJ, Leiper JM, Vallance P. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res. 2002;90(7):764-769. https://doi.org/10.1161/01.RES.0000014450.40853.2B
Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, Homma K, Yoshioka K, Sugano N, Saruta T. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005;28(3):255-262. https://doi.org/10.1291/HYPRES.28.255
Monsalve E, Oviedo PJ, García-Pérez MA, Tarín JJ, Cano A, Hermenegildo C. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc Res. 2007;73(1):66-72. https://doi.org/10.1016/J.CARDIORES.2006.09.020
Tanaka M, Osanai T, Murakami R, Sasaki S, Tomita H, Maeda N, Satoh K, Magota K, Okumura K. Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine. J Hypertens. 2006;24(3):489-497. https://doi.org/10.1097/01.HJH.0000209985.66853.1E
Sorrenti V, Mazza F, Campisi A, Vanella L, Li Volti G, Di Giacomo C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res. 2006;3(1):49-54. https://doi.org/10.2174/156720206775541778
Knodler LA, Sekyere EO, Stewart TS, Schofield PJ, Edwards MR. Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis. J Biol Chem. 1998;273(8):4470-4477. https://doi.org/10.1074/JBC.273.8.4470
Frey D, Braun O, Briand C, Vasák M, Grütter MG. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: a basis for the design of specific inhibitors. Structure. 2006;14(5):901-911. https://doi.org/10.1016/J.STR.2006.03.006
Birdsey GM, Leiper JM, Vallance P. Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand. 2000;168(1):73-79. https://doi.org/10.1046/J.1365-201X.2000.00672.X
Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293(6): H3227-3245. https://doi.org/10.1152/AJPHEART.00998.2007
Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr. 2003;22(1):17-22. https://doi.org/10.1054/clnu.2002.0612
Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52(6):1593-1601. https://doi.org/10.1038/KI.1997.490
Bultink IE, Teerlink T, Heijst JA, Dijkmans BA, Voskuyl AE. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(9):1362-1365. https://doi.org/10.1136/ARD.2005.036137
Kozlova AA, Ragavan VN, Jarzebska N, et al. Divergent dimethylarginine dimethylaminohydrolase isoenzyme expression in the central nervous system. Cell Mol Neurobiol. 2022;42(7):2273-2288. https://doi.org/10.1007/S10571-021-01101-7
Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4(4):53-60. https://doi.org/10.1016/S1567-5688(03)00034-5
Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, Losordo DW, Isner JM. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol. 1999;19(5):1156-1161. https://doi.org/10.1161/01.ATV.19.5.1156
Vallance P, Leiper J. Blocking NO synthesis: how, where and why? Nat Rev Drug Discov. 2002;1(12):939-950. https://doi.org/10.1038/nrd960
Clarke S. Protein methylation. Curr Opin Cell Biol. 1993;5(6):977-983. https://doi.org/10.1016/0955-0674(93)90080-A
Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20(Suppl. 12):S60-S62. https://doi.org/10.1097/00005344-199204002-00018
Wells SM, Holian A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol. 2007;36(5):520-528. https://doi.org/10.1165/RCMB.2006-0302SM
Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24(6):1023-1030. https://doi.org/10.1161/01.ATV.0000128897.54893.26
Kittel A, Maas R. Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases. Curr Pharm Des. 2014;20(22):3530-3547. https://doi.org/10.2174/13816128113196660750
Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109(15):1813-1818. https://doi.org/10.1161/01.CIR.0000126823.07732.D5
Franceschelli S, Ferrone A, Pesce M, Riccioni G, Speranza L. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci. 2013;14(12):24412-24421. https://doi.org/10.3390/IJMS141224412
Hu X, Atzler D, Xu X, et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol. 2011;31(7):1540-1546. https://doi.org/10.1161/ATVBAHA.110.222638
Iyengar R, Stuehr DJ, Marletta MA. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. Proc Natl Acad Sci USA. 1987;84(18):6369-6373. https://doi.org/10.1073/PNAS.84.18.6369
Kimoto M, Tsuji H, Ogawa T. N (G), N (G)-Dimethyl-l-arginine, a dominant precursor of endogenous dimethylamine in rats. Amino Acids. 1994;6(3):273-282. https://doi.org/10.1007/BF00813747
Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315-424. https://doi.org/10.1152/PHYSREV.00029.2006
Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun. 2003;308(4):984-989. https://doi.org/10.1016/S0006-291X(03)01507-9
Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, Cooke JP. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. 2005;111(11):1431-1438. https://doi.org/10.1161/01.CIR.0000158487.80483.09
Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol. 2007;49(10):1099-1105. https://doi.org/10.1016/j.jacc.2006.10.068
Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost. 2000;26(5):529-537. https://doi.org/10.1055/s-2000-13209
Parveen SMA, Natani S, Sruthi KK, Khilar P, Ummanni R. HIF-1α and Nrf2 regulates hypoxia induced overexpression of DDAH1 through promoter activation in prostate cancer. Int J Biochem Cell Biol. 2022;147:106232. https://doi.org/10.1016/J.BIOCEL.2022.106232
Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer. 2002;87(6):673-680. https://doi.org/10.1038/SJ.BJC.6600518
Wojciak-Stothard B, Torondel B, Tsang LY, Fleming I, Fisslthaler B, Leiper JM, Vallance P. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci. 2007;120(Pt. 6):929-942. https://doi.org/10.1242/JCS.002212
Liu XJ, Hong Q, Wang Z, Yu YY, Zou X, Xu LH. MicroRNA21 promotes interstitial fibrosis via targeting DDAH1: a potential role in renal fibrosis. Mol Cell Biochem. 2016;411(1-2):181-189. https://doi.org/10.1007/S11010-015-2580-2
Ramachandran I, Thavathiru E, Ramalingam S, et al. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012;31(22):2725-2737. https://doi.org/10.1038/ONC.2011.455
Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005;179(1-2):56-65. https://doi.org/10.1159/000084509
Wang Y, Hu S, Gabisi AM Jr, Er JA, Pope A, Burstein G, Schardon CL, Cardounel AJ, Ekmekcioglu S, Fast W. Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma. ChemMedChem. 2014;9(4):792-797. https://doi.org/10.1002/CMDC.201300557
Ye J, Xu J, Li Y, Huang Q, Huang J, Wang J, Zhong W, Lin X, Chen W, Lin X. DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/β-catenin signaling pathway. Mol Oncol. 2017;11(9):1208-1224. https://doi.org/10.1002/1878-0261.12089
Kami Reddy KR, Dasari C, Vandavasi S, Natani S, Supriya B, Jadav SS, Sai Ram N, Kumar JM, Ummanni R. Novel cellularly active inhibitor regresses DDAH1 induced prostate tumor growth by restraining tumor angiogenesis through targeting DDAH1/ADMA/NOS pathway. ACS Comb Sci. 2019;21(4):241-256. https://doi.org/10.1021/ACSCOMBSCI.8B00133
Buijs N, Oosterink JE, Jessup M, Schierbeek H, Stolz DB, Houdijk AP, Geller DA, van Leeuwen PA. A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. Angiogenesis. 2017;20(4):557-565. https://doi.org/10.1007/S10456-017-9567-4
Boult JK, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, Robinson SP. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol. 2011;225(3):344-352. https://doi.org/10.1002/PATH.2904
Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Sci Rep. 2017;7(1):13996. https://doi.org/10.1038/S41598-017-14454-1
Hulin JA, Tommasi S, Elliot D, Mangoni AA. Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro. Biomed Pharmacother. 2019;111:602-612. https://doi.org/10.1016/j.biopha.2018.12.117

Закрыть метаданные